Skip to main content

Advertisement

Log in

NEURODEGENERATION

Biomarkers for Alzheimer’s disease beyond amyloid and tau

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Two new biomarkers for Alzheimer’s disease include one in the blood that relates to neurodegeneration and another that reflects blood–brain barrier dysfunction and is identifiable in cerebrospinal fluid analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: New early biomarkers for neurodegeneration.

References

  1. Preische, O. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0304-3 (2019).

  2. Nation, D.A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0297-y (2019).

  3. Jansen, W. J. et al. JAMA Psychiatry 75, 84–95 (2018).

    Article  Google Scholar 

  4. Ashton, N. J. et al. Biomark Med. 12, 799–812 (2018).

    Article  CAS  Google Scholar 

  5. Fagan, A. M. et al. Sci. Transl. Med. 6, 226ra230 (2014).

    Article  Google Scholar 

  6. Maia, L. F. et al. Sci. Transl. Med. 5, 194re192 (2013).

    Article  Google Scholar 

  7. Sato, C. et al. Neuron 98, 861–864 (2018).

    Article  CAS  Google Scholar 

  8. Okamura, N. et al. Clin. Transl. Imaging 6, 305–316 (2018).

    Article  Google Scholar 

  9. Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimers Dement. (NY) 4, 195–214 (2018).

    Google Scholar 

  10. Rasmussen, M. K., Mestre, H. & Nedergaard, M. Lancet Neurol. 17, 1016–1024 (2018).

    Article  CAS  Google Scholar 

  11. Khalil, M. et al. Nat. Rev. Neurol. 14, 577–589 (2018).

    Article  CAS  Google Scholar 

  12. Bergman, J. et al. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Henrik Zetterberg.

Ethics declarations

Competing interests

H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures–based platform company at the University of Gothenburg. J.M.S. has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zetterberg, H., Schott, J.M. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med 25, 201–203 (2019). https://doi.org/10.1038/s41591-019-0348-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0348-z

  • Springer Nature America, Inc.

This article is cited by

Navigation